Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $46.4 million.

  • Tg Therapeutics' Cash from Investing Activities rose 59671.09% to $46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year increase of 17344.22%. This contributed to the annual value of -$1.0 million for FY2024, which is 9795.46% up from last year.
  • As of Q3 2025, Tg Therapeutics' Cash from Investing Activities stood at $46.4 million, which was up 59671.09% from -$4.0 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Cash from Investing Activities registered a high of $46.4 million during Q3 2025, and its lowest value of -$44.8 million during Q4 2023.
  • For the 5-year period, Tg Therapeutics' Cash from Investing Activities averaged around -$2.2 million, with its median value being -$2.5 million (2021).
  • In the last 5 years, Tg Therapeutics' Cash from Investing Activities tumbled by 839630.35% in 2022 and then surged by 59671.09% in 2025.
  • Over the past 5 years, Tg Therapeutics' Cash from Investing Activities (Quarter) stood at $3.3 million in 2021, then skyrocketed by 394.8% to $16.3 million in 2022, then plummeted by 375.09% to -$44.8 million in 2023, then soared by 135.28% to $15.8 million in 2024, then soared by 193.66% to $46.4 million in 2025.
  • Its last three reported values are $46.4 million in Q3 2025, -$4.0 million for Q2 2025, and -$12.9 million during Q1 2025.